Design and Synthesis of Novel DFG-Out RAF/Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitors. 1. Exploration of [5,6]-Fused Bicyclic Scaffolds

Citations Over TimeTop 10% of 2012 papers

Abstract

To develop RAF/VEGFR2 inhibitors that bind to the inactive DFG-out conformation, we conducted structure-based drug design using the X-ray cocrystal structures of BRAF, starting from an imidazo[1,2-b]pyridazine derivative. We designed various [5,6]-fused bicyclic scaffolds (ring A, 1-6) possessing an anilide group that forms two hydrogen bond interactions with Cys532. Stabilizing the planarity of this anilide and the nitrogen atom on the six-membered ring of the scaffold was critical for enhancing BRAF inhibition. The selected [1,3]thiazolo[5,4-b]pyridine derivative 6d showed potent inhibitory activity in both BRAF and VEGFR2. Solid dispersion formulation of 6d (6d-SD) maximized its oral absorption in rats and showed significant suppression of ERK1/2 phosphorylation in an A375 melanoma xenograft model in rats by single administration. Tumor regression (T/C = -7.0%) in twice-daily repetitive studies at a dose of 50 mg/kg in rats confirmed that 6d is a promising RAF/VEGFR2 inhibitor showing potent anticancer activity.

Related Papers

• → The synthesis of pyridazino[4,5‐d] pyridazines, pyrazino [2,3‐d] pyridazines and a pyrimido [4,5‐d] pyridazine(1968)24 cited
• → A convenient and facile synthesis of pyridine, pyridazine, pyrimido-[4,5-c]pyridazine, pyrido[3,4-c]pyridazine, 1,6-naphthyridine and phthalazine derivatives(2006)16 cited
• → The synthesis of imidazo[4,5‐c] ‐ and v‐triazolo[4,5‐c] pyridazines(1967)24 cited
• → Studies on the Syntheses of N-Heterocyclic Compounds. XII. Syntheses of Pyrido[3, 4-d]pyridazine and Pyrido[2, 3-d]pyridazine Derivatives(1972)4 cited
• → The synthesis of pyrazino[2,3‐d]pyridazine and some of its derivatives(1966)20 cited